文献速递病毒性肝炎

恩替卡韦停药与持续治疗对HBsAg清除的影响

The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy.
PubMed 文献 · J Infect Dis · 2019-01-01

该研究比较了HBeAg阴性无肝硬化患者停用或继续恩替卡韦治疗后的HBsAg清除率和HCC发生率。停药组(n=234)5年累积HBsAg清除率为13%,且停药是HBsAg清除的独立预测因素,两组HCC发生无显著差异。

要点

  • 停药组5年累积HBsAg清除率为13%。
  • 停药组HBsAg清除率高于继续治疗组。
  • 两组HCC发生率无显著差异。

核心结论

  • HBeAg阴性无肝硬化患者停用恩替卡韦后HBsAg清除率更高,且不增加HCC风险。

研究设计与样本

  • 研究纳入停药至少12个月的患者234例和继续治疗至少4年的患者226例。

主要发现

  • 停药组5年累积病毒学复发率为71.9%,临床复发率为58.9%,HBsAg清除率为13%。
  • 持续应答、病毒学复发无临床复发、临床复发未再治疗者发生HBsAg清除的可能性分别是再治疗者的49倍、13倍和18倍。
  • 停药组HBsAg清除率高于继续治疗组,在全人群和360对倾向评分匹配患者中均如此。
  • Cox回归显示停药组是HBsAg清除的独立预测因素。
  • 两组HCC发生在全人群和倾向评分匹配患者中均无显著差异。

临床怎么用

  • 对于HBeAg阴性无肝硬化的慢乙肝患者,可考虑停用恩替卡韦以提高HBsAg清除机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We compared rates of hepatitis B surface antigen (HBsAg) loss and hepatocellular carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative patients without cirrhosis who continued or discontinued entecavir. METHODS: Patients who discontinued entecavir treatment for at least 12 months (discontinued group; n = 234) and patients who continued entecavir treatment for at least 4 years (continued group; n = 226) were recruited. RESULTS: In the discontinued group, the 5-year cumulative incidences of virological relapse (VR), clinical relapse (CR), and HBsAg loss were 71.9%, 58.9%, and 13%, respectively. Patients with sustained response, VR but no CR, and CR without retreatment were 49-, 13-, and 18-fold more likely to develop HBsAg loss than those with retreatment. Patients who discontinued entecavir therapy had a higher rate of HBsAg loss than those who continued entecavir therapy, in all and 360 propensity score (PS)-matched patients. Cox regression analysis revealed that the discontinued group was an independent predictor for HBsAg loss. There was no significant difference in HCC development between the 2 groups in all and PS-matched patients. CONCLUSIONS: HBeAg-negative patients without cirrhosis who discontinued entecavir treatment exhibited a higher HBsAg loss rate without an increased risk of HCC compared to those who continued entecavir treatment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen CH, Hung CH, Wang JH, et al. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019. PMID: 30689910. doi:10.1093/infdis/jiy697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。